Protalix BioTherapeutics
Develops and manufactures plant-cell-derived enzyme therapies for rare diseases.
Something off on this page? Send us feedback.
Profile
Develops and manufactures plant-cell-derived recombinant protein therapies for Gaucher and Fabry diseases, earning product-supply and milestone revenue through commercialization partners. Its integrated model combines a proprietary expression platform and Israeli production site with partner-controlled global distribution.
Develops recombinant protein therapies for rare diseases through ProCellEx, a plant-cell suspension expression platform. Approved enzyme-replacement products include Elelyso for Gaucher disease and Elfabrio for Fabry disease, while PRX-115 is in clinical development for uncontrolled gout.
Manufactures commercial drug substance and clinical material at its Carmiel, Israel facility, pairing in-house discovery and production with partner-led commercialization. Pfizer markets Elelyso outside Brazil, Chiesi commercializes Elfabrio globally, and Fiocruz distributes the Brazilian taliglucerase alfa presentation.
Revenue comes chiefly from product deliveries and milestones under these collaborations and is recognized when inventory reaches partners rather than when patients use it. Operations depend on a single Israeli manufacturing site, continued product approvals, partners' commercial execution, and pipeline progress.
Company facts
Key statistics
Year to date +45.7% · Average volume (30d) 709.7K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Aug 13, 2026 | Raymond James | Initiate | Strong Buy | $6 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q2 FY26 | −$0.01 | $0.05 | +600.0% | $13.0M | $19.9M | +53.6% | +7.82% |
| May 13, 2026Q1 FY26 | −$0.01 | $0.22 | +2,300.0% | $11.5M | $33.8M | +193.5% | +3.63% |
| Mar 18, 2026Q4 FY25 | $0.01 | −$0.07 | −800.0% | $18.3M | $9.1M | −50.1% | +0.90% |
| Nov 13, 2025Q3 FY25 | $0.06 | $0.03 | −50.0% | $14.2M | $17.9M | +25.3% | −3.63% |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $10.1M | $15.7M | $17.9M | $9.1M | $33.8M | $19.9M | |
| Gross profit | $1.9M | $9.8M | $9.5M | $4.5M | $29.6M | $12.1M | |
| Operating income | −$4.1M | $1.2M | $2.1M | −$4.7M | $21.1M | $4.7M | |
| Net income | −$3.6M | $164.0K | $2.4M | −$5.5M | $18.3M | $3.8M | |
| Diluted EPS | −$0.05 | $0.00 | $0.03 | −$0.07 | $0.22 | $0.05 | |
| Gross margin | 19.1% | 62.5% | 53.4% | 49.4% | 87.8% | 61.0% | |
| Operating margin | -41.0% | 7.5% | 11.9% | -51.1% | 62.7% | 23.5% |
Fiscal years (4-quarter sums)FY24 $53.4M · FY25 $52.7M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $40.7M · Total debt $9.2M · Total assets $110.3M · Shareholders' equity $71.4M
Dividends
No dividends on record.
Ownership
Shares outstanding 80.57M · Float 77.45M · 96.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 4.05M | 5.02% | 13G | Jul 29, 2026 |
| Mak Capital One LLC | 3.54M | 4.40% | 13F | May 15, 2026 |
| Renaissance Technologies LLC | 1.22M | 1.52% | 13F | May 14, 2026 |
| State Street Corp | 972.8K | 1.21% | 13F | May 15, 2026 |
| Northern Trust Corp | 885.4K | 1.10% | 13F | May 14, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Sanofi (ADR)
Broad established rival across Gaucher and Fabry disease therapy.
- Takeda (ADR)
Dual enzyme-replacement rival in Gaucher and Fabry disease.
- Amgen
Approved uricase benchmark for uncontrolled gout.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Protalix BioTherapeutics | $2.58 | +1.87% | $204.7M | 11.0 | — | 2.5 | +27.1% |
| Sanofi (ADR) | $44.83 | +0.02% | $107.62B | 78.9 | — | 1.9 | +11.2% |
| Takeda (ADR) | $18.49 | +2.53% | $57.37B | 51.0 | 53.7 | 2.0 | +5.8% |
| Amgen | $430.27 | −0.49% | $233.38B | 26.9 | 18.4 | 6.1 | +9.7% |
| Median | 51.0 | 36.1 | 2.0 | +9.7% |